On June 15, 2021 Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson’s disease and related disorders inside and outside of the brain, reported that the pricing of an underwritten public offering of 15 million shares of its common stock at a public offering price of $3.00 per share for total gross proceeds of approximately $45 million (the "Offering) before deducting underwriting discounts and commissions and offering expenses payable by Inhibikase(Press release, Inhibikase Therapeutics, JUN 16, 2021, View Source [SID1234584072]). In addition, Inhibikase has granted the underwriters a 45-day option to purchase up to 2.25 million additional shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on June 18, 2021, subject to customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Inhibikase intends to use the net proceeds from the public offering, together with existing funds, to fund the costs of a Phase 1b extension study for IkT-148009 in Parkinson’s patients and to validate target engagement markers in the central and peripheral nervous system; to fund production of IkT-148009 for Phase 1b and Phase 2 clinical studies and to fund a Phase 2 efficacy trial of IkT-148009 in Parkinson’s patients. This funding will further support the clinical dose calibration study(ies) of IkT-001Pro in healthy subjects to support approval under the Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act and to fund drug product production for IkT-001Pro. The balance will support general research and development activities, medicinal chemistry for additional molecules and IND-enabling studies, team building, and other general corporate activities

ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering. JonesTrading Institutional Services LLC is acting as the co-manager for the offering.

The offering is being made pursuant to a registration statement on Form S-1 (File No. 333-257032) that was declared effective by the Securities and Exchange Commission (the "SEC") on June 15, 2021. This offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained, when available, from the offices of ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673, or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.

On June 16, 2021 ImmunoPrecise reported that it will be attending The 6th Annual CAR-TCR Summit which returns in 2021 as the industry-leading comprehensive forum with one goal: to engineer a disease-free world(Press release, ImmunoPrecise Antibodies, JUN 16, 2021, View Source [SID1234584070]). At the event, over 150 speakers will lead discussions on many topics from commercial pipeline development to new innovations and approaches. The virtual event will be held from August 30 to September 2.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On June 14, 2021 Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, reported that it has entered into a definitive securities purchase agreement with several institutional investors for the issuance and sale of an aggregate of 3,866,667 shares of its common stock at a purchase price of $7.50 per share of common stock a registered direct offering priced at-the-market under Nasdaq rules(Press release, Enochian BioSciences, JUN 16, 2021, View Source [SID1234584069]). The registered direct offering is expected to close on or about June 16, 2021, subject to the satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The gross proceeds from the offering are expected to be approximately $29 million before deducting placement agent fees and other offering expenses. Enochian currently intends to use the net proceeds from the offering for working capital and general corporate purposes.

The securities described above are being offered pursuant to Enochian’s shelf registration statement on Form S-3 (File No. 333-239837) filed with the Securities and Exchange Commission (the "SEC") on July 13, 2020 and declared effective on July 20, 2020. Such securities may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and the accompanying prospectus relating to the securities being offered in the registered direct offering will be filed with the SEC. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, on the SEC’s website at View Source or by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, NY 10022, by e-mail: [email protected] or by telephone: (212) 856-5711.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of any of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

On June 16, 2021 GT Biopharma, a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager (TriKE) protein biologic technology platform, reported that it will provide a corporate update at the upcoming Raymond James Human Health Innovation Conference on Tuesday, June 22, 2021 at 11:20 AM ET (Press release, GT Biopharma, JUN 16, 2021, View Source [SID1234584068]).
A live webcast of the event will be available by visiting "Presentations" page in the Investors section of GT Biopharma’s website at www.gtbiopharma.com/news-media/presentations. A replay of the webcast will be archived for 30 days following the presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On June 16, 2021 LMU Munich reported that it’s researchers have identified the 14-3-3sigma gene as an important suppressor of carcinogenesis in the gastrointestinal tract (Press release, LMU Munich, JUN 16, 2021, View Source [SID1234584067]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Intestinal cancers, also known as colorectal cancer, are among the most prevalent forms of malignancy worldwide. If detected early enough, tumors can be surgically excised. However, as cancer growth progresses, cells may escape from the primary tumor, which can then establish metastatic tumors in other organs. Once such satellite tumors have formed, survival rates fall significantly. Formation of the initial tumor can be triggered by mutations in any of a number of genes. Together with postdocs Markus Winter and Matja� Rokavec, Professor Heiko Hermeking at LMU’s Institute of Pathology has now discovered that a gene called 14-3-3sigma functions as a tumor suppressor in gastrointestinal cancers. Using the mouse as an experimental model, the team demonstrated that inactivation of the 14-3-3sigma gene enhance progression of gastrointestinal cancers and consequently shortens the lifespan of mice.

In earlier work with colon carcinoma cell lines, Hermeking and his colleagues had shown that a protein known as p53, which plays a central role in the suppression of many types of tumors, activates the 14-3-3sigma gene, and that its protein product inhibits passage through the cell cycle. This brake on cell division gives cells more time to repair adventitious or environmentally caused DNA damage, and therefore reduces the risk of uncontrolled cell proliferation. Mutations that inactivate p53 are found in more than half of all tumors. "But it was not clear whether the 14-3-3sigma gene itself plays an important role in the suppression of tumorigenesis in the intestine," says Hermeking.

In a project funded by the German Cancer Research Fund (Deutsche Krebshilfe), his team set out to clarify this issue by analyzing patterns of gene expression in several thousands of tumor samples isolated from patients with colorectal cancer. The data revealed that the expression of 14-3-3sigma is indeed significantly downregulated in these tumors. In addition, this effect was particularly pronounced in metastatic tumors, and the level of expression of the gene showed a negative correlation with the degree of cancer progression. Furthermore, patients with lower levels of expression of the 14-3-3sigma gene were found to have a worse prognosis than those with higher expression – and this finding was independent of whether or not the tumors also contained an inactivating mutation in the p53 gene.

To further explore the significance of 14-3-3sigma in intestinal carcinogenesis, the LMU researchers specifically inactivated the gene in a preclinical mouse model of intestinal cancer. Loss of the gene’s function was found to stimulate the formation and growth of tumors in the gastrointestinal tract, and ultimately reduced survival times. Subsequent studies showed that, in the absence of the 14-3-3sigma gene, signaling pathways which are regulated by transcription factors that have been implicated in the formation of metastases are selectively induced. Interestingly, the 14-3-3sigma protein is known to bind and negatively regulate these transcription factors. "Taken together, our results demonstrate that 14-3-3sigma is not only one of the many target genes that are controlled by p53 and mediate its tumor-suppressing function, but also has tumor-suppressive functions on its own in the gastrointestinal tract," says Hermeking.

The authors of the study suggest that detection of decreased expression of the 14-3-3sigma gene in resected primary colon carcinomas could serve as a prognostic indicator in patient populations. "Moreover, the signaling pathways that are triggered upon its inactivation are potential targets for therapeutic interventions," Hermeking adds.